The first study conducted with MV140 in North America has been presented at the American Urological Association’s annual conference (Chicago, IL) 

MV140 is a polybacterial mucosal vaccine developed by INMUNOTEK for the prevention of recurrent uncomplicated urinary tract infections. This type of infection affects preferentially the urinary bladder (cystitis) in women, being its current treatment based on the use of antibiotics. Previous results obtained in Europe have demonstrated the efficacy and safety of MV140 in reducing the number of infections and antibiotic consumption.

MV140 SUBLINGUAL VACCINE REDUCES RISK OF RECURRENT URINARY TRACT INFECTION (RUTI) IN NORTH AMERICAN WOMEN: RESULTS FROM THE FIRST NORTH AMERICAN CLINICAL EXPERIENCE STUDY

J. Curtis Nickel, Dean Elterman, Kerri-Lynn Kelly, Ashley Griffin, and R. Christopher Doiron

This real-world study was prospectively performed in Canada by Dr. Nickel and colleagues on 67 women suffering from this type of infection. The results showed a reduction rate of these infections of almost 75%, in line with previous studies.

+info

---